MHRA Approves Vimseltinib (romvimza) for Tenosynovial Giant Cell Tumours

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved vimseltinib (romvimza) for the treatment of adult patients with tenosynovial giant cell tumour (TGCT) when the condition impacts movement or surgery is not a viable option. TGCT is a rare, non-cancerous tumor affecting joints and tendons.